Eupraxia Pharmaceuticals Inc.
EPRXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 1, 2026 | H.C. Wainwright | Brandon Folkes | $11.00(+21%) | $9.10 | StreetInsider |
| Sep 24, 2026 | Wedbush | $17.00(+109%) | $8.14 | TheFly | |
| Sep 24, 2026 | Stifel Nicolaus | Samimy Annabel | $25.00(+207%) | $8.14 | StreetInsider |
| Jun 25, 2026 | Oppenheimer | $17.00(+165%) | $6.41 | TheFly | |
| Jan 15, 2026 | Cantor Fitzgerald | $19.00(+125%) | $8.43 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Oct 1, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 4, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 22, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 17, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Jan 15, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 9, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 20, 2025 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.16 | $-0.23 | — | — |
| May 12, 2026 | $-0.23 | $-0.22 | — | — |
| Mar 12, 2026 | $-0.37 | $-0.16 | — | — |
| Nov 4, 2025 | $-0.19 | $-0.23 | — | — |
| Aug 12, 2025 | $-0.26 | $-0.21 | — | — |
| May 6, 2025 | $-0.21 | $-0.19 | — | — |
| Mar 20, 2025 | $-0.21 | $-0.18 | — | — |
| Nov 7, 2024 | $-0.17 | $-0.13 | — | — |
News
VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company's management team will participate in the following upcoming conferences and host a virtual Analyst Day: Craig Hallum Biotech Cat…
VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the ongoing RESOLVE study evaluating the safety and efficacy of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”) has reached it…
VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today is pleased to announce that three abstracts related to Company's ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis …
VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced updated clinical data from the Phase 1b/2a RESOLVE study highlighting the long duration of response, high remission rates and tolerability of EP-…
VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (Nasdaq: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced today that its common shares have commenced trading on the Nasdaq Global Select Market.
The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post treatment In the same analysis, 23% of patients reported severe odynophagia at baseline; and no patients reported severe odynophagia at the 24 and 52 weeks timepoints The number of patients experiencing moderate to severe dysphagia (difficulty swallowing) in Cohorts 7-9 was reduced from 77% at baseline …
New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI
The consensus price target hints at a 145.4% upside potential for Eupraxia Pharmaceuticals Inc. (EPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.